Welcome to our dedicated page for ViewRay news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on ViewRay stock.
ViewRay, Inc. (Nasdaq: VRAY) is a trailblazer in the field of MRI-guided adaptive radiotherapy. The company designs, manufactures, and markets the MRIdian® radiation therapy system, an innovative solution aimed at addressing the key limitations of conventional external-beam radiation therapy technologies. Using cutting-edge MRI-based technology, the MRIdian system provides real-time imaging that precisely distinguishes the targeted tumor from surrounding soft tissue and critical organs during radiation treatment.
One of the standout features of the MRIdian system is its capability to record the level of radiation exposure the tumor receives and adapt the treatment prescription as needed. This adaptive approach enhances the safety and efficacy of radiation therapy, which ViewRay believes will lead to better patient outcomes.
ViewRay has established itself as a visionary in the medical field, dedicated to providing doctors with advanced tools to improve cancer treatment through radiation therapy. The company prides itself on its entrepreneurial spirit and unwavering commitment to innovation and excellence.
Among its recent achievements, ViewRay announced that the VA Oklahoma City Healthcare System has selected the MRIdian system to expand its radiation therapy services. This marks the first cancer center in Oklahoma to offer Veterans access to MRIdian's advanced MRI-guided radiation therapy. The system will enable precision treatment for various cancers, including pancreas, prostate, lung, liver, breast, and oligometastatic disease.
The Veterans Health Administration, the largest integrated healthcare system in America, is actively incorporating MRIdian technology across multiple VA medical centers. This expansion highlights the growing recognition of MRIdian's short-course non-invasive therapy, which promises fewer side effects and improved quality of life for patients.
To date, over 31,000 patients worldwide have been treated using MRIdian systems, with 62 installations in hospitals across the globe. These systems are employed to treat a diverse range of solid tumors and are subjects of numerous ongoing research studies. The MRIdian system has been featured in hundreds of peer-reviewed publications and scientific presentations, underscoring its clinical significance and impact.
For a list of treatment centers utilizing MRIdian technology, visit ViewRay's website.
ViewRay (Nasdaq: VRAY) will showcase its MRIdian® Linac MRI-guided radiation therapy system at the ASTRO 2020 Annual Meeting from October 24-28. Nearly 40 presentations will highlight the system's effectiveness in treating challenging cancers, including pancreatic and renal tumors. Studies from various institutions will present data supporting MRIdian's clinical value, emphasizing its ability to personalize treatments. ViewRay will also host Innovation Hub presentations and a physician-led webinar for investors on October 27, focusing on MRIdian's capabilities and clinical experiences.
ViewRay, Inc. (Nasdaq: VRAY) has announced a conference call on November 5, 2020 to discuss its third quarter 2020 financial results. The call will begin at 4:30 p.m. ET, with a live webcast available on their investor relations page. This announcement comes as the company prepares to share insights on its financial performance and future operating outlook. ViewRay specializes in manufacturing the MRIdian MR-Guided Radiation Therapy System, designed to improve treatment outcomes in radiation oncology.
On October 14, 2020, ViewRay, Inc. (Nasdaq: VRAY) announced the purchase of its MRIdian Linac MRI-Guided Therapy System by the Louis Stokes Cleveland VA Medical Center. This advanced system enhances radiation therapy by allowing real-time visualization of tumors, adaptive treatment based on anatomical changes, and protection of healthy tissue. Patients can benefit from fewer treatment sessions, ranging from one to five, compared to the conventional 25 to 40 sessions. ViewRay currently has 39 MRIdian systems in use globally, having treated over 10,000 patients.
ViewRay (Nasdaq: VRAY) will host a virtual physician-led informational discussion for investors and analysts during the 2020 ASTRO Annual Meeting on October 27, 2020, from 9:00 a.m. to 10:00 a.m. MTN. Registration is required and will close one hour before the start. The session will feature guest speakers like Dr. John Bayouth and Daphne Haas-Kogan, MD. An archived replay will be available within 24 hours on ViewRay's investor relations website.
ViewRay, Inc. (Nasdaq: VRAY) announced that Chungnam National University Sejong Hospital in South Korea has commenced patient treatments using the MRIdian MRI-Guided Therapy System. This advanced radiation therapy technology allows for real-time tumor tracking and adaptive treatment, enhancing patient safety and treatment efficacy. As of now, there are 39 MRIdian systems installed globally, having treated over 10,000 patients. The integration of MRIdian supports CNUH's commitment to providing state-of-the-art cancer care.
ViewRay, Inc. (NASDAQ: VRAY) announced participation in three virtual investor conferences scheduled for September 2020. The first event is the Cantor Virtual Global Healthcare Conference on September 16, followed by the Morgan Stanley 18th Annual Global Healthcare Conference on September 18 at 11:00 am ET. Finally, ViewRay will attend the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23 at 2:30 pm ET. Replays of the fireside chats will be available for 14 days post-presentation.
ViewRay, Inc. (Nasdaq: VRAY) announced a significant milestone, with the treatment of 10,000 patients using its MRIdian MRI-Guided Radiation Therapy System, the first system combining MR imaging with radiation delivery. This advanced technology allows for real-time tumor tracking and adaptive therapy, increasing treatment efficacy while minimizing damage to healthy tissue. Since its inception in January 2014 at Siteman Cancer Center, MRIdian has gained recognition as a pioneering tool in oncology. The company currently operates 38 MRIdian systems worldwide, contributing to ongoing research and development in cancer care.
ViewRay, Inc. (Nasdaq: VRAY) has launched a Compassionate Access Programme in collaboration with GenesisCare and the University of Oxford to provide MRI-guided radiation therapy for NHS patients with localized pancreatic cancer in the UK. Eligible patients, who are unable to undergo surgery or chemotherapy, will receive treatment at GenesisCare's Oxford center free of charge, thanks to support from the Pancreatic Cancer Research Fund. This initiative aims to enhance patient access to advanced treatment during the COVID-19 pandemic and generate clinical data on its effectiveness to expand availability.
ViewRay (Nasdaq: VRAY) announced that Dartmouth-Hitchcock Health in New Hampshire has initiated patient treatments using the MRIdian MRI-Guided Therapy System. This advanced technology enhances radiation therapy precision by employing MRI for soft-tissue visualization, allowing tailored treatment plans for individual patients. With 38 MRIdian systems currently operational globally, this expansion aims to improve non-invasive cancer treatment access.
The system is supported by substantial research, with over 9,000 patients treated, highlighting its role in innovative cancer care.
ViewRay, Inc. (Nasdaq: VRAY) announced that Kaohsiung Medical University Chung-Ho Memorial Hospital in Taiwan has commenced patient treatments using the MRIdian MR-Guided Radiation Therapy System. This state-of-the-art system enhances personalized cancer care by utilizing advanced imaging and automated beam-gating technology. The first two patients treated were for prostate cancer and lung tumors. MRIdian’s ability to adapt treatments in real-time helps protect healthy tissue while delivering precise radiation doses. This installation marks the first MRIdian system in Taiwan and the fifth in Asia, contributing to nearly 10,000 patients treated globally.
FAQ
What does ViewRay, Inc. specialize in?
What is the MRIdian® system?
What recent achievement has ViewRay announced?
How many patients have been treated with the MRIdian system?
How many MRIdian systems are currently installed worldwide?
What types of cancer can be treated with MRIdian?
Why is MRIdian considered advanced in radiation therapy?
What are some common side effects of radiation therapy with MRIdian?
Is MRIdian suitable for all patients?
Where can I find more information about MRIdian treatment centers?
